Werkgroep Cardiologische centra Nederland

STRENGTH (Follow-up)

Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
Medicine
epanova
Population
ASCVD
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Director of Study

dr. A.F.M. Kuijper (Cardioloog)
Haarlem, Spaarne Gasthuis